<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390608</url>
  </required_header>
  <id_info>
    <org_study_id>365</org_study_id>
    <nct_id>NCT03390608</nct_id>
  </id_info>
  <brief_title>Prognostic and Predictive Factors for Small Breast Tumors</brief_title>
  <official_title>Prognosis, Prognostic Factors and Predictive Factors in Centimeter or Subcentimeter Node-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Society of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Breast Cancer Association (BRO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because of mammography screening increasingly more women are diagnosed with centimeter or
      subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for
      approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term
      relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports
      suggest that certain patient subgroups may have rates &lt;75%. Firmly established prognostic and
      predictive factors for patients with T1abN0 tumors are, however, lacking. This is a
      nationwide, register-based cohort study investigating prognostic and predictive factors in
      women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1)
      Established prognostic and/or predictive factors in overall breast cancer are prognostic
      and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2)
      The established relative reduction in risk of recurrence and death of adjuvant treatment for
      overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 1977</start_date>
  <completion_date type="Actual">July 30, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Breast cancer specific death</measure>
    <time_frame>January 1, 1977 to December 31, 2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>January 1, 1977 to July 30, 2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metachronous breast cancer</measure>
    <time_frame>January 1, 1977 to July 30, 2016</time_frame>
    <description>Ipsilateral or contralateral breast cancer</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">35002</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy versus no radiotherapy.</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Trastuzumab versus no trastuzumab (in women with HER2-positive disease).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy versus no chemotherapy.</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Type of breast cancer surgery</intervention_name>
    <description>Type of surgery (partial mastectomy, mastectomy, other).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Age at diagnosis</intervention_name>
    <description>Age at diagnosis (&lt;35, 35-&lt;50, 50-&lt;70, ≥70).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Screen detected tumor</intervention_name>
    <description>Screening detected tumor (yes, no).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Menopausal status at diagnosis</intervention_name>
    <description>Menopausal status (premenopausal, postmenopausal).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor size</intervention_name>
    <description>Tumor size (≤5 mm, 6-≤10 mm).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Estrogen receptor (ER) status</intervention_name>
    <description>ER-status (positive, negative).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor grade</intervention_name>
    <description>Tumor grade (1, 2, 3).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HER2-status</intervention_name>
    <description>HER2-status (positive, negative).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intrinsic subgroups of breast cancer</intervention_name>
    <description>Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nodal status</intervention_name>
    <description>N-status (N0, N1).</description>
    <arm_group_label>Women with T1ab breast cancer.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of all Swedish women operated for centimeter or subcentimeter
        breast cancer who are included in the regional breast cancer registries (1977 to 2007) or
        the national breast cancer registry (2008 onwards).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female.

          2. Operated for centimeter or subcentimeter breast cancer.

        Exclusion Criteria:

          1. Previous breast cancer.

          2. Metastatic breast cancer at diagnosis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska Instiutet</name>
      <address>
        <city>Solna</city>
        <zip>17177</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Andreas Pettersson</investigator_full_name>
    <investigator_title>Researcher, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

